Stage IV lung cancer response followed by immune-related lung inflammation

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative

Metastatic Site: pleura

After the lung inflammation improved, he did not resume tumor-directed chemotherapy, immunotherapy, or radiation and remained generally well.

PubMed CentralRead more →

Stage III lung cancer treatment complicated by immune-related lung inflammation

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: EGFR-negative; ALK-negative; ROS1-negative

Mediastinal lymph nodes later enlarged despite additional systemic treatment, prompting radiation and further therapy.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; later ALK mutation after progression

Metastatic Site: Bone — pelvis and spine/L5

Living with Stage IV lung cancer on a clinical trial after progression, with current treatment described as working and quality of life improved.

The Patient StoryRead more →

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Patient Story

Patient Info: Daniel West, Male, 50s | Stage II

Biomarkers: EGFR positive

As of April 2026, Daniel had shown no evidence of active disease for more than 2 years, while remaining on daily osimertinib through June 2026 and receiving checkups and scans every 3 months for stable monitored lung nodules.

MD AndersonRead more →

Synchronous Stage IA lung adenocarcinoma and grade 4 glioblastoma: lung nodule regressed during brain-cancer therapy

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Lung molecular biomarkers not reported; glioblastoma biomarker details not summarized in library fields

The Stage IA lung adenocarcinoma was monitored without lung-directed therapy and decreased from 18 mm to 9 mm while CNS-directed glioblastoma treatment continued; she remained alive with no lung cancer progression.

PubMed CentralRead more →

Stage IIIA lung adenocarcinoma: major pathological response after neoadjuvant immunochemotherapy, complicated by DILI/TEN

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: No lung molecular biomarkers reported

At 23 months after thoracoscopic left upper lobectomy, he was clinically stable with no evidence of tumor recurrence; severe postoperative DILI/TEN had improved after stopping the offending drug and intensive supportive treatment.

PubMed CentralRead more →

Recurrent lung adenocarcinoma with isolated pancreatic metastasis: Whipple resection after discordant tumor-origin testing

Patient Info: Anonymized, Female, 70+ | Stage Metastatic/Advanced

Biomarkers: Pancreatic lesion showed KRAS

Metastatic Site: mediastinal lymph node; pancreas

After prior lung surgery, adjuvant chemotherapy, and later chemoradiation for mediastinal nodal recurrence, an isolated pancreatic lesion was resected by Whipple procedure; post-Whipple recurrence status was not yet reported.

PubMed CentralRead more →

Small-cell lung cancer: envafolimab response complicated by immune-related diabetes, pneumonitis, and later submandibular progression

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: ProGRP and NSE were elevated at diagnosis. Tumor molecular biomarkers were not reported; diabetes antibodies were negative.

Metastatic Site: left submandibular region / adjacent lymph nodes

After initial partial response on envafolimab, carboplatin, etoposide, and thoracic radiotherapy, he developed immune-related diabetes, pneumonitis, and progressive left submandibular metastatic disease requiring iodine-125 seeds and later anlotinib.

PubMed CentralRead more →

Stage III EGFR Lung Cancer: Roxanne's Patient Story

Patient Info: Roxanne, Female, 40s | Stage III

Biomarkers: EGFR mutation

Roxanne had Stage III EGFR-mutated lung cancer after surgery found mediastinal lymph-node involvement. As of March 2026, she was living with the long-term effects of surgery, chemotherapy, radiation, and ongoing EGFR-targeted therapy, while also managing the emotional and financial burden of cancer as a single parent.

The Patient StoryRead more →

Stage IV Non-Small Cell Lung Cancer: Natalie's Patient Story

Patient Info: Natalie, Female, Under 40 | Stage IV

Metastatic Site: Spine

Natalie was living with Stage IV NSCLC after a double lung transplant gave her new lung function, but cancer later appeared in the spine and required renewed chemotherapy and radiation.

The Patient StoryRead more →

Stage IV EGFR-positive lung cancer treated for nearly 5 years before progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR L858R mutation

Metastatic Site: liver

The cancer later progressed despite chemotherapy, and he died from lung cancer 4 years and 8 months after diagnosis.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Maggie's Patient Story

Patient Info: Maggie, Female, 60s | Stage IV

Biomarkers: EGFR mutation; MET amplification resistance mutation; MET overexpression

Metastatic Site: Brain

Maggie initially reached no evidence of disease on EGFR-targeted therapy, but later had repeated progression, including MET-amplification resistance and MET overexpression, requiring SBRT, a clinical trial, chemotherapy, and later-line targeted treatment.

The Patient StoryRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Clara's Patient Story

Patient Info: Clara, Female, Under 40 | Stage IV

Biomarkers: ALK-positive / ALK-rearranged after repeat Tempus testing

Metastatic Site: Pelvis; spleen

As of February 2026, ALK-targeted therapy had improved Clara’s symptoms enough that she no longer needed a walker or cane, and upcoming scans would determine whether pelvic tumor surgery remained an option.

The Patient StoryRead more →

Stage IVB lung adenocarcinoma with severe immune-related complications

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 TPS 20%; BRAF mutation

Metastatic Site: left supraclavicular fossa, left axilla, right hilum,…

The patient had an initial partial response to ipilimumab/nivolumab but developed severe immune-related pneumonitis, thrombocytopenia, and aplastic anemia. Cytopenias recovered with eltrombopag, but lung cancer later relapsed with carcinomatous meningitis, and he died 20 months after diagnosis.

PubMed CentralRead more →

Stage IV ROS1 Lung Cancer: Phil's Patient Story

Patient Info: Phil, Male, 60s | Stage IV

Biomarkers: ROS1 mutation

Metastatic Site: Lymph nodes; other lung

Phil was living with incurable Stage IV ROS1-positive lung cancer. After initial chemotherapy, a ROS1-targeted pill worked for about 2 years, and he later continued on a Mass General clinical-trial treatment with follow-up every 3 months.

The Patient StoryRead more →

Extensive-stage small-cell lung cancer with malignant superior vena cava syndrome

Patient Info: Anonymized, Male, 60s

After superior vena cava stenting, facial and upper-extremity edema improved, he was discharged on hospital day 7, and he lived at home without recurrent SVCS symptoms until death from worsening lung cancer about 2 months later.

PubMed CentralRead more →

Pulmonary epithelioid hemangioendothelioma with complete response after neoadjuvant therapy

Patient Info: Anonymized, Male, 60s

Biomarkers: WWTR1-CAMTA1 fusion; vascular markers supported epithelioid hemangioendothelioma; lung cancer markers were absent.

The patient achieved radiographic disappearance of the lung tumor after neoadjuvant paclitaxel/carboplatin plus bevacizumab. Surgery then showed no residual tumor and lymph nodes were negative; CT follow-up through April 2024 showed no recurrence.

PubMed CentralRead more →

Locally advanced lung adenocarcinoma: neoadjuvant treatment, surgery, and fistula repair

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Three months after reconstruction for postoperative esophagopleural fistula, her nutritional status had improved and esophagogram showed no anastomotic leak; long-term lung cancer control was not reported.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Stephanie's Patient Story

Patient Info: Stephanie, Female, 40s | Stage IV

Biomarkers: ALK mutation / ALK-positive

Metastatic Site: ovaries; spine; liver; lung

Stage IV ALK-positive NSCLC is being managed with ALK-directed treatment; follow-up scans were described as improving, but the source does not state complete remission.

The Patient StoryRead more →

Stage 4 lung cancer: large tumor managed with targeted care

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 TPS <1%

Metastatic Site: contralateral lymph nodes, supraclavicular lymph…

The patient had a partial response to CheckMate 9LA despite PD-L1 TPS <1%, later progressed after 24 cycles of immunotherapy, received additional chemotherapy, and died in November 20XX+2.

PubMed CentralRead more →

EGFR-mutant lung adenocarcinoma with acquired ROS1 rearrangement after EGFR-TKI resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; acquired EZR exon10-ROS1 exon34 rearrangement

Metastatic Site: bone (distal femur); contralateral lung;…

After fourth-line crizotinib for acquired EZR-ROS1 rearrangement, response evaluation on August 27, 2025 showed partial response, and September 2025 bone scan showed stable bone lesions.

PubMed CentralRead more →

Kidney damage as a rare side effect of durvalumab immunotherapy

Patient Info: Anonymized, Male, 70+

The lung-cancer burden decreased during treatment. Durvalumab was stopped because of nephrotic syndrome, which achieved sustained complete remission with prednisolone.

PubMed CentralRead more →

Stage 4 lung cancer: persistent cough led to diagnosis

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS and TP53 ; PD-L1 TPS 95%. Other common lung drivers were not detected.

Metastatic Site: liver, left adrenal gland, lymph nodes, pleural…

After more than 2 years of disease control and partial response on antiangiogenic therapy plus sintilimab, the patient developed fulminant immune-checkpoint-inhibitor-induced type 1 diabetes with severe diabetic ketoacidosis, inflammatory crisis, sepsis, and died shortly after discharge against medical advice.

PubMed CentralRead more →

EGFR-Mutant Lung Adenocarcinoma With Bone and Leptomeningeal Metastases

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: bone, leptomeninges

In May 2025, leptomeningeal disease remained present and he continued combination chemotherapy with bevacizumab and high-dose furmonertinib, leaving hospital in stable condition after cycle 8.

PubMed CentralRead more →